Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Part of paid clinical trials in Dublin, Ohio.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT06345183
- Status
- Completed
Conditions
- Advanced Renal Cell Carcinoma (aRCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab + Ipilimumab combination therapy — COMBINATION_PRODUCTAs per product label
- Pembrolizumab + Lenvatinib combination therapy — COMBINATION_PRODUCTAs per product label
Study Details
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Key Dates
- First listed
- Apr 3, 2024
- Start date
- Feb 19, 2024
- Status verified
- Nov 2025
- Primary completion
- Apr 4, 2024
- Completion
- Apr 4, 2024
Study Design
- Enrollment
- 327 participants (actual)
Arms
- Arm: Participants treated with Nivolumab + Ipilimumab combination therapy
- Arm: Participants treated with Pembrolizumab + Lenvatinib combination therapy
Primary Outcome Measure
Participant year of birth [ Time Frame: Baseline ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cardinal Health | Dublin | Ohio | 43017 | - |
Find similar trials in Dublin, OH
By research site
Related Studies
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)PHASE2 · Recruiting · Brian Rini · Nashville, Tennessee